Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease
By Colin Kellaher
Vertex Pharmaceuticals has won U.S. Food and Drug Administration clearance to study its VX-407 drug candidate in certain patients with the most common inherited kidney disease.
Vertex on Thursday said it will study VX-407 in patients with autosomal dominant polycystic kidney disease, or ADPKD, who have a subset of PKD1 genetic variants.
The Boston drugmaker said it plans to launch a Phase 1 study in healthy volunteers this month, making ADPKD its 10th disease area in the clinic.
Vertex said some 250,000 people in the U.S. and Europe suffer from ADPKD, with no treatments currently available that address the underlying causal biology of the disease. The company added that the majority of ADPKD cases are caused by variants in the PKD1 gene.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 21, 2024 08:33 ET (12:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth